Join
Live feed
·
PRReleasevia Quantisnow
Allarity Therapeutics Inc. logo

Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

ByQuantisnow·Wall Street's wire, on your screen.
ALLR· Allarity Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALLR (Allarity Therapeutics Inc.) and more on Quantisnow.